Allogene Therapeutics (ALLO) Current Deferred Revenue (2020 - 2024)
Allogene Therapeutics (ALLO) posted Current Deferred Revenue of $86000.0 for Q1 2024, little changed sequentially from $86000.0 in Q4 2023, and little changed YoY from $86000.0 in Q2 2023.
Allogene Therapeutics (ALLO) Current Deferred Revenue (2020 - 2024) Analysis & Trends
Allogene Therapeutics has reported Current Deferred Revenue for 5 years, with the latest figure at $86000.0 in Q1 2024.
- Quarterly Current Deferred Revenue changed 0.0% year-over-year to $86000.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $86000.0 (changed 0.0% YoY) and the FY2023 annual result came in at $86000.0, down 9.47% from the prior year.
- Current Deferred Revenue held at $86000.0 in Q1 2024 per ALLO's latest filing, from $86000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $39.0 million in Q4 2020 and troughed at $86000.0 in Q1 2023.
- A 5-year average of $2.9 million and a median of $101500.0 in 2022 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2021 and 2024: Current Deferred Revenue slumped 99.6% in 2021, then changed 0.0% in 2024.
- Over 5 years, Current Deferred Revenue stood at $39.0 million in 2020, then slumped by 99.6% to $156000.0 in 2021, then tumbled by 39.1% to $95000.0 in 2022, then slipped by 9.47% to $86000.0 in 2023, then changed by 0.0% to $86000.0 in 2024.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $86000.0, $86000.0, and $86000.0 for Q1 2024, Q4 2023, and Q3 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 86,000.00 |
| Dec 31, 2023 | 86,000.00 |
| Sep 30, 2023 | 86,000.00 |
| Jun 30, 2023 | 86,000.00 |
| Mar 31, 2023 | 86,000.00 |
| Dec 31, 2022 | 95,000.00 |
| Sep 30, 2022 | 99,000.00 |
| Jun 30, 2022 | 104,000.00 |
| Mar 31, 2022 | 147,000.00 |
| Dec 31, 2021 | 156,000.00 |
| Sep 30, 2021 | 365,000.00 |
| Jun 30, 2021 | 305,000.00 |
| Mar 31, 2021 | 239,000.00 |
| Dec 31, 2020 | 38.99 Mn |